CA9 and nonpapillary renal cell carcinoma: Carbonic anhydrase IX (CAIX), a downstream gene product of hyperactivation of the hypoxia inducible factor (HIF) pathway, represents an important therapeutic target for patients with ccRCC [10, 11].